Clinical trials: Best Disease
Colorectal Cancer, Quality of Life
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00079066
- Testing
- cetuximab, quality-of-life assessment
- Where
- 33 sites in Australia, Canada
- Volunteers
- 572 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Colorectal Cancer
Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
Colorectal cancer (CRC) accounts for 10% to 15% of all cancers and is the second leading cause of cancer deaths in Western countries.
- Trial name
- NCT02060669
- Testing
- Xeloda
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Samsung Medical Center
Intestinal Microbiome, Febrile Neutropenia
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
The purpose of this study is to see how different antibiotics affect the community of friendly bacteria existing in the intestinal tract (gut).
- Trial name
- NCT03078010
- Testing
- Piperacillin-tazobactam, cefepime
- Where
- 2 sites in United States
- Volunteers
- 347 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Asymptomatic, Artery
Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis
Background. Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA).
- Trial name
- NCT00497094
- Testing
- carotid artery stenting
- Where
- Austria
- Volunteers
- 148 people
- Sponsor
- Vienna General Hospital
Chronic Kidney Disease
Sevelamer in Proteinuric CKD
Progressive renal impairment in chronic kidney diseases (CKD) may cause inability to excrete phosphate load, thus leading to the typical abnormalities of the mineral metabolism, such as increased phosphate and reduced calcium…
- Trial name
- ANSWER (NCT01968759)
- Testing
- Sevelamer, Ramipril and Irbesartan
- Where
- 2 sites in Italy
- Volunteers
- 53 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Essential Thrombocythemia
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant…
- Trial name
- NCT06079879
- Testing
- Bomedemstat, Anagrelide, Busulfan
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01773187
- Testing
- Pacritinib, Best Available Therapy
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 327 people
- Sponsor
- CTI BioPharma
Diabetic Kidney Disease
Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine
Background: Diabetic kidney disease (DKD) is chronic and often progresses to kidney failure,heart disease and premature death. Unfortunately, the best medical therapies available for DKD today are ultimately unable to prevent its…
- Trial name
- PROMISE (NCT02011178)
- Testing
- Optimal medical treatment and surgery, Optimal medical treatment
- Where
- 2 sites in Sweden, Switzerland
- Sponsor
- Karolinska Institutet
Myelodysplastic Syndrome
Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes
REGIME is comparing two treatments, with Darbepoetin Alpha (DA) and Filgrastim (Granulocyte Colony Stimulating Factor, G-CSF), to the standard treatment for Myelodysplastic Syndrome (MDS).
- Trial name
- REGIME (NCT01196715)
- Testing
- Darbepoetin alpha, Filgrastim, Blood Red Cell Transfusion
- Where
- 4 sites in United Kingdom
- Volunteers
- 360 people
- Sponsor
- Barts & The London NHS Trust
Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA.
- Trial name
- NCT04557735
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 26 sites in United States, Israel and 5 more
- Volunteers
- 41 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pancreatic Cancer
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
No Standard therapy has been approved for third-line therapy of advanced pancreatic cancer. K001 is peptidoglycan prepared from the marine microorganism, with an anti-tumor activity.
- Trial name
- NCT04183478
- Testing
- K-001
- Where
- China
- Volunteers
- 600 people
- Sponsor
- RenJi Hospital
Urothelial Carcinoma
Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy
This is a 2-arm, prospective, randomized (2:1 ratio), open-label, multi-centre, phase II study conducted in patients affected by unresectable, locally advanced or metastatic urothelial cancer receiving niraparib plus best…
- Trial name
- NCT03945084
- Testing
- Niraparib, Best supportive care
- Where
- 20 sites in Italy
- Volunteers
- 58 people
- Sponsor
- University of Turin, Italy
Ruptured Aneurysm of Intracranial Artery
DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment
The purpose of the DIVERT study is to provide a prudent, controlled clinical context for the use of flow diversion, a promising option of yet unproven benefit, in the care of patients with acute blood blister-like and dissecting…
- Trial name
- DIVERT (NCT01976026)
- Testing
- Flow Diversion, Best Standard Therapy
- Where
- Canada
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Bronchiolitis
Monitoring OXYgen in Infants Hospitalized With Bronchiolitis: A Best Practices Trial (The MOXY Trial)
In infants hospitalized with bronchiolitis, a common infection in the lungs caused by a virus, it is uncertain on how to best monitor their oxygen levels.
- Trial name
- NCT01646606
- Testing
- Intermittent oxygen monitoring, Continuous oxygen monitoring
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- The Hospital for Sick Children
IBS - Irritable Bowel Syndrome
Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients
Researchers are trying to determine the best course of action regarding the dietary management with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP diet) for irritable bowel syndrome.
- Trial name
- NCT03948854
- Testing
- Registered dietitian, On-line video program, Printed handout
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Schizophrenia
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs.
- Trial name
- BEST (NCT00712270)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Kettering Health Network
Essential Thrombocythemia
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Prospective national multicenter randomized open label phase IIb RUXBETA trial.
- Trial name
- NCT02962388
- Testing
- Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα
- Where
- France
- Volunteers
- 13 people
- Sponsor
- French Innovative Leukemia Organisation
Coronavirus Infection
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia
In early December 2019, cases of pneumonia of unknown origin were identified in Wuhan, China. The causative virus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- COP-COVID-19 (NCT04358783)
- Testing
- Plasma, Best Available Therapy
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Ménière's Disease
Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers
The goal of this pharmakokinetic trial is to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone.
- Trial name
- PK-BesT (NCT05938517)
- Testing
- Betahistine dihydrochloride, Selegiline-hydrochloride
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Retinitis Pigmentosa
Oral N-acetylcysteine for Retinitis Pigmentosa
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations.
- Trial name
- NAC Attack (NCT05537220)
- Testing
- N-acetylcysteine
- Where
- 31 sites in United States, Austria and 5 more
- Volunteers
- 485 people
- Sponsor
- Johns Hopkins University